Status:

COMPLETED

Evaluation of Long-term Buprenorphine Plasma Exposure

Lead Sponsor:

Indivior Inc.

Conditions:

Opioid-use Disorder

Eligibility:

All Genders

Brief Summary

The study objective is to characterise the long-term plasma exposure to buprenorphine after stopping SUBLOCADE treatment. There are no interventions planned. This multicentre investigation will enrol...

Detailed Description

Data indicate that after discontinuing SUBLOCADE patients may have detectable concentrations of buprenorphine in plasma and urine for 12 months or longer. Previous Phase II/III studies did not evaluat...

Eligibility Criteria

Inclusion

  • Participated in Study RB-US-13-0003 or both Studies RB-US-13-0003 and INDV-6000-301 and received at least 2 subcutaneous (SC) injections of SUBLOCADE
  • Within 12 to 36 months post his or her last SUBLOCADE injection at the time of the Screening Visit
  • Female individuals of childbearing potential must agree to have a pregnancy test administered prior to enrollment and throughout the study. Pregnancy does not prohibit participation
  • Willing to adhere to study procedures and provide written informed consent prior to the start of any study procedures.

Exclusion

  • Received SUBLOCADE or any other long-acting buprenorphine product at any time after ending their participation in Study RB-US-13-0003 or Study INDV-6000-301
  • Taken any buprenorphine (prescribed or illicit) within 3 weeks prior to the Screening visit (study Part A, Visit 1)

Key Trial Info

Start Date :

February 19 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 18 2019

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT03752528

Start Date

February 19 2019

End Date

July 18 2019

Last Update

August 21 2020

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Pathway Healthcare

Hamilton, Alabama, United States, 35570

2

Meridian Research

Tampa, Florida, United States, 33606

3

Phoenix Medical Research

Prairie Village, Kansas, United States, 66208

4

Adams Clinical

Watertown, Massachusetts, United States, 02472